Wells Fargo analyst Mohit Bansal lowered the firm’s price target on Bristol Myers (BMY) to $60 from $65 and keeps an Equal ...

Johnson & Johnson trades at a higher valuation with growing sales, while Pfizer's dividend yield is near 6% as patents expire from 2026 through 2030.

A brief research report found that Medicare beneficiaries taking several commonly prescribed medications could see ...

Bristol-Myers Squibb is a Hold as replacing lost revenue from Eliquis and Opdivo presents a significant challenge. Click here ...

Pfizer is rated a Buy with new and acquired products generated $3.2B in Q2, growing 18% YoY and $13B annualized run-rate.

I recently retired and signed  up for a Medicare Advantage plan in 2026.  I take Xarelto 20 mg and through government ...

PFE moves above its 50-day SMA as newer drugs, oncology and obesity treatments fuel growth prospects, but declining COVID ...

WASHINGTON (AP) — Millions of Americans who buy cheap drugs from Canada could soon lose access when a customs rule goes into ...

Medicare negotiated the price of 10 popular medications to save enrollees money. Even more medications are scheduled for negotiation in the coming years.

Leerink's David Risinger downgrades Bristol Myers to market perform and cuts his price target to $59, citing doubts on ...

TAHO Pharmaceuticals (6467.TW) will transition from Taiwan's emerging stock market to a main board listing on October 20, ...

- Bristol Myers BMY-0.77% (BMY) and Novo Nordisk NVO+1.20% (NVO) trade at similar low P/E ratios but reflect divergent risks: ...